Yue He, MD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 in Phase 3

Quick facts

Phase 3 pipeline

Camrelizumab and Cetuximab · Oncology
Camrelizumab blocks PD-1 to enhance immune response while cetuximab blocks EGFR to inhibit tumor cell growth, combining immunotherapy with targeted therapy.
Camrelizumab and Chemotherapy · Oncology
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, used in combination with chemotherapy to enhance cancer cell killing.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Yue He, MD portfolio CI brief
Yue He, MD pipeline updates RSS

Frequently asked questions about Yue He, MD

What is Yue He, MD's pipeline?

Yue He, MD has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Camrelizumab and Cetuximab, Camrelizumab and Chemotherapy.

Sector hub: All tracked pharma companies